Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
BMY Bristol-Myers Squibb
72.450-0.540-0.74%
Close
01/27 16:00 ET
72.300-0.150-0.21%
Post Mkt Price 01/27 17:49 ET
High
73.450
Open
72.990
Turnover
394.73M
Low
72.340
Pre Close
72.990
Volume
5.43M
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
The Use of Artificial Intelligence in Medical Devices and Drug Development
Spire Wealth Management Cuts Stake in Bristol-Myers Squibb (NYSE:BMY)
Spire Wealth Management reduced its position in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 43.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exch
Preview -- Barron's
Monday 1/30 Franklin Resources, GE HealthCare Technologies, and NXP Semiconductors report quarterly results. Tuesday 1/31 Advanced Micro Devices, Amgen, Caterpillar, Chubb, Edwards Lifesciences, El
Arvest Trust Co. N A Increases Position in Bristol-Myers Squibb (NYSE:BMY)
Arvest Trust Co. N A increased its stake in Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 54.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commiss
Private Portfolio Partners LLC Sells 241 Shares of Bristol-Myers Squibb (NYSE:BMY)
Private Portfolio Partners LLC lessened its stake in Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 0.6% during the third quarter, according to its most recent filing with the Securities and Exchan
Bristol Myers Squibb Co. Stock Falls Friday, Underperforms Market
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Bristol Myers Squibb Co. (BMY) slid 0.74% to $72.45 Friday, on what proved to be an all-aro
The Power of Dual Immunotherapy
NORTHAMPTON, MA / ACCESSWIRE / January 27, 2023 / Originally published on Bristol Myers Squibb News & PerspectivesA decade ago, the evolution of immuno-oncology transformed the landscape of therapy fo
Bristol-Myers Squibb's Reblozyl Receives Positive Opinion From European Medicines Agency
07:53 AM EST, 01/27/2023 (MT Newswires) -- Bristol-Myers Squibb Company (BMY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval o
Bristol Myers Gets CHMP Backing for Sotyktu, Reblozyl >BMY
By Colin Kellaher Bristol Myers Squibb Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended initial approval of its psoriasis drug Sotyktu
Bristol-Myers Announces CHMP Opinion Recommending Approval for Reblozyl
Company Overview
More
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
CEO： Dr. Giovanni Caforio, M.D.
Market： NYSE
Listing Date： 06/01/1969
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet